Powles T, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. ASCO-GU 2019, abstract 543.
25ste Nationale Longkanker Symposium
feb 2024 | Chirurgie, Immuuntherapie, Longoncologie, Radiotherapie